Related Experiment Video

Updated: Nov 28, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.8K

Anti-angiogenic therapy for ovarian cancer

Yolanda García García1, Maria Marín Alcalá1, Clara Martínez Vila1

  • 1Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí, I3PT. Universitat Autònoma de Barcelona, Parc Taulí 1, Sabadell, 08208, Barcelona, Spain.

EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]
|November 26, 2020
PubMed

Insights

Anti-angiogenic drugs are vital for treating ovarian cancer, showing effectiveness alone or with other therapies. This review covers their mechanisms, clinical use, and safety in various treatment settings.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is a critical process in ovarian cancer development and spread.
  • Anti-angiogenic therapies represent a significant advancement in ovarian cancer treatment strategies.

Purpose of the Study:

  • To review the mechanism of action, clinical efficacy, and safety of key anti-angiogenic drugs for ovarian cancer.
  • To evaluate these agents in neoadjuvant, first-line, and relapsed ovarian cancer settings.

Main Methods:

  • Literature review of anti-angiogenic agents in ovarian cancer treatment.
  • Analysis of drug mechanisms, clinical trial data, and safety profiles.

Main Results:

  • Anti-angiogenic agents demonstrate activity in ovarian cancer, both as monotherapy and in combination regimens.
  • These drugs are utilized across different treatment phases, including neoadjuvant, first-line, and relapsed settings.

Conclusions:

  • Anti-angiogenic therapies are integral to modern ovarian cancer management.
  • Understanding their role is crucial for optimizing treatment outcomes and patient care.
Keywords:
afliberceptantiangiogenic therapybevacizumabcediranibnintedanibovarian cancerpazopanibtrebananib

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.2K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
908
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K